Form 4: United Therapeutics Director Jan Malcolm Reports Initial Stock and Option Awards

Jan Malcolm, a new director at United Therapeutics, reports the acquisition of stock options and restricted stock units as part of the Non-Employee Director Compensation Program.

Summary

• Jan Malcolm, a new director of United Therapeutics Corporation, filed a Form 4 to report changes in beneficial ownership.
• The report details the acquisition of stock options and restricted stock units (RSUs) awarded on June 26, 2024, in accordance with the Non-Employee Director Compensation Program.
• Malcolm acquired 1,520 stock options with an exercise price of $318.95, vesting fully on June 26, 2025, and expiring on June 26, 2034.
• She also acquired 630 restricted stock units, each representing the right to receive one share of United Therapeutics common stock upon vesting, which also occurs on June 26, 2025.
• Following these transactions, Malcolm directly owns 1,520 stock options and 630 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard compensation practice for a new director, aligning interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

Granting stock options and restricted stock units to non-employee directors is a common practice to align their interests with the long-term success of the company and its shareholders. This aligns with standard compensation practices in the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) also utilize stock options and restricted stock units as part of their director compensation packages.
• The specific amounts and vesting schedules can vary based on company size, performance, and industry benchmarks.
• The vesting period of one year is fairly standard for director equity grants.

Stakeholder Impact

• The grant of equity to the new director aligns her interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates